Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Endocrinology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Diabetes Mellitus, Type 2 Clinical Trials

A listing of Diabetes Mellitus, Type 2 medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (186) clinical trials

Study With Dapagliflozin

Objectives and Hypotheses: Primary objective: To describe HbA1c (glycosylated haemoglobin) change from baseline to follow-up Secondary objectives: Clinical data: To estimate percentage (%) of patients with reduction of HbA1c by 0.5% or more from baseline to follow-up To estimate percentage (%) of patients reaching the therapeutic glycemic response (HbA1c <7.0%) ...

Phase N/A

Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice

The drug being studied in this study is called alogliptin and alogliptin FDCs. Alogliptin and alogliptin FDCs is being researched to treat people who have diabetes mellitus type 2. This study will look at the glycosylated hemoglobin (HbA1c) level dynamics in participants with diabetes mellitus type 2. The study will ...

Phase N/A

Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors

Type 2 diabetes mellitus remains a major risk factor for cardiovascular disease with an estimated 425 million adults worldwide having diabetes in 2017, with type 2 diabetes mellitus accounting for about 90% of the cases. Recent evidence indicates that certain glucose-lowering therapies are associated with reduction in cardiovascular outcomes. There ...

Phase N/A

Qatar Universal Diabetes Outcomes (QUDOS) Study

QUDOS aims to gain a better understanding of diabetes in primary and secondary care over a period of 24 months. A range of patients with diabetes will be sampled (including those with Type 1 diabetes as this group is under-studied in Qatar). This will be important in designing appropriate intervention ...

Phase N/A

Do Patient-Centric mHealth Programs Improve Patient Engagement and Health Outcomes.

The proposed pilot program is the first of its kind in the nation to use a product, "IntelliH" - Intelligent Health for All, that combines four key technologies in one platform: Mobile health application (mHealth) App and web portal, 2) wireless sensors and wearable devices, 3) Secure text messaging when ...

Phase N/A

Dapagliflozin Patient Satisfaction Survey

This is a cross-sectional, observational patient survey study. Study subjects will be adult commercial members of the large US health plan affiliated with Optum with evidence of T2D initiating dapagliflozin or a sulfonylurea medication within the 3 months prior to survey mailing.

Phase N/A

Assessing Progression to Type-2 Diabetes (APT-2D): A Prospective Cohort Study Expanded From BRITE-SPOT (Bio-bank and Registry for StratIfication and Targeted intErventions in the Spectrum Of Type 2 Diabetes)

This is a prospective open cohort study. The study will comprise the following periods: Screening Complete screening checklist and informed consent form Procedures. Following the screening visit, subjects are required to return to undergo the following: Oral Glucose Tolerance Test (OGTT) to assess glucose tolerance and beta cell function Frequently-Sampled ...

Phase N/A

JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus

To monitor the safety profile and effectiveness of Empagliflozin in Korea patients with type 2 diabetes mellitus in a routine clinical practice setting

Phase N/A

PASS to Assess Risk of Renal Injury Hepatic Injury Diabetic Ketoacidosis and Infections in Empagliflozin-treated Patients

Empagliflozin (Jardiance), a highly potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), was approved in Europe in May 2014 for the treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic control in adults. As part of the risk management plan, Boehringer Ingelheim International GmbH (BI) has committed ...

Phase N/A

Progression of Coronary Atherosclerosis in Asymptomatic Diabetic Subjects

Hypothesis: We hypothesise that a combination of CT coronary angiography, ultrasound of the heart and of the arteries of the neck, evaluation of expression of genetic markers and bio-markers in the blood will help identify diabetic patients at highest risk of heart disease progression,that can result in angina, heart attacks, ...

Phase N/A